Compare MXCT & DOMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MXCT | DOMO |
|---|---|---|
| Founded | 1999 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 136.0M | 132.7M |
| IPO Year | 2021 | 2018 |
| Metric | MXCT | DOMO |
|---|---|---|
| Price | $1.19 | $3.53 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 9 |
| Target Price | $5.50 | ★ $10.28 |
| AVG Volume (30 Days) | 1.4M | ★ 3.0M |
| Earning Date | 05-12-2026 | 05-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 31.92 |
| EPS | ★ N/A | N/A |
| Revenue | $33,026,000.00 | ★ $318,857,000.00 |
| Revenue This Year | N/A | $3.41 |
| Revenue Next Year | $18.50 | $4.72 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 0.57 |
| 52 Week Low | $0.64 | $1.84 |
| 52 Week High | $2.37 | $18.49 |
| Indicator | MXCT | DOMO |
|---|---|---|
| Relative Strength Index (RSI) | 57.63 | 56.66 |
| Support Level | $1.08 | $3.32 |
| Resistance Level | $1.30 | $4.07 |
| Average True Range (ATR) | 0.07 | 0.36 |
| MACD | -0.00 | 0.12 |
| Stochastic Oscillator | 46.40 | 94.71 |
MaxCyte Inc is a life sciences company focused on advancing the discovery, development, and commercialization of next-generation cell therapies. It uses its proprietary cell engineering technology platform to support biotechnology and pharmaceutical customers in cell therapy, gene editing, immuno-oncology, and biologic development. It operates in one segment: cell engineering technology, which generates revenue mainly from product sales, licenses, research and clinical license fees, and program-related revenues as its SPL customers achieve development and regulatory milestones. Its platform, the ExPERT Platform, is based on Flow Electroporation technology designed to efficiently and safely modify human cells with high efficiency, low cytotoxicity, and scalability for clinical use.
Domo Inc provides a cloud-based platform that digitally connects all the data, systems, and people in an organization, giving them access to real-time data and insights and allowing them to manage their business from their smartphones. The company offers a platform to its customers as a subscription-based service. Users receive notifications on any device and immediately act on the invitation, after which the system can write back to the original system of record. The company derives revenue from subscriptions to its cloud-based platform and professional services.